Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE: **NEW ASSIGNMENT** NATURE OF CONVEYANCE: ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL

CONVEYING PARTY DATA

| Name | Formerly | Execution Date | Entity Type |
|------------------------------------|----------|----------------|-----------------------|
| Medicis Pharmaceutical Corporation | | 12/03/2007 | CORPORATION: DELAWARE |

RECEIVING PARTY DATA

| Name: | Taro Pharmaceuticals U.S.A., Inc. | |
|-------------------|---------------------------------------|--|
| Street Address: | 3 Skyline Drive | |
| Internal Address: | c/o Taro Pharmaceuticals U.S.A., Inc. | |
| City: | Hawthorne | |
| State/Country: | NEW YORK | |
| Postal Code: | 10532 | |
| Entity Type: | CORPORATION: NEW YORK | |

PROPERTY NUMBERS Total: 6

| Property Type | Number | Word Mark |
|----------------------|---------|----------------|
| Registration Number: | 2618880 | ALUSTRA |
| Registration Number: | 2204466 | LUSTRA |
| Registration Number: | 2329449 | LUSTRA |
| Registration Number: | 2427453 | LUSTRA-AF |
| Registration Number: | 3133987 | LUSTRA ULTRA |
| Registration Number: | 2478612 | SUNANDSKIN.COM |

CORRESPONDENCE DATA

Fax Number: (206)224-0779

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

2066828100 Phone: Email: efiling@cojk.com

Correspondent Name: Daiva K. Tautvydas, Esq. 1420 Fifth Avenue, Suite 2800 Address Line 1:

Christensen O'Connor Johnson Kindness PL Address Line 2:

TRADEMARK **REEL: 003677 FRAME: 0818**

| Address Line 4: Seattle, WASHINGTON 98101 | | | |
|--|----------------------|--|--|
| ATTORNEY DOCKET NUMBER: | MDPC-5-22712 | | |
| NAME OF SUBMITTER: | Daiva K. Tautvydas | | |
| Signature: | /Daiva K. Tautvydas/ | | |
| Date: | 12/13/2007 | | |
| Total Attachments: 4 source=SDOC1899#page1.tif source=SDOC1899#page2.tif source=SDOC1899#page3.tif source=SDOC1899#page4.tif | | | |

TRADEMARK REEL: 003677 FRAME: 0819

ASSIGNMENT OF TRADEMARKS

WHEREAS, Medicis Pharmaceutical Corporation, a Delaware corporation, having its principal place of business at 8125 North Hayden Road, Scottsdale, AZ 85258 ("Medicis") and Taro Pharmaceuticals U.S.A., Inc., a New York corporation, having its principal place of business at c/o Taro Pharmaceuticals U.S.A., Inc., 3 Skyline Drive, Hawthorne, New York 10532 ("Taro," sometimes referred to herein individually as a "Party" and collectively with Medicis as the "Parties") have entered into that certain License and Option Agreement dated as of July 29, 2004, as amended ("License and Option Agreement");

WHEREAS, pursuant to the License and Option Agreement, Taro desires to acquire the entire right, title and interest in, to and under the trademark registrations listed on the attached Exhibit A (collectively, the "Marks");

WHEREAS, Medicis is the respective owner of the Marks; and

WHEREAS, pursuant to the terms of the License and Option Agreement, Medicis has agreed to assign the Marks, goodwill and other rights associated therewith to Taro under this agreement ("Assignment") upon the Closing Date (as defined in the License and Option Agreement).

NOW, THEREFORE, for the good and valuable consideration, to it in hand paid by Taro, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Medicis does hereby sell, assign, transfer and set over to Taro all of Medicis' right, title and interest in, to and under the Marks and registrations, and all applications and renewals in connection therewith, together with the goodwill of the business symbolized by the Marks, together with all rights and privileges granted and secured thereby, including the right to sue and recover for any past infringement, the rights to be held and enjoyed by Taro, for its own use and benefit and for the use and benefit of its successors, assigns or other legal representatives as fully and entirely as the same would have been held and enjoyed by Medicis if this Assignment had not been made.

This Assignment of Trademarks, dated as of December 3, 2007, may be executed in counterparts, each of which shall constitute an original and all of which, when taken together, shall constitute one and the same Assignment of Trademarks. A facsimile transmitted signature to this Assignment of Trademarks shall be deemed an acceptable written approval of each respective Party to the actions taken herein.

[Signature page follows.]

1

| | parties hereto have executed this Assignment by its |
|---|--|
| proper officers thereunto duly authorized. | |
| | MEDICIS PHARMACEUTICAL |
| | CORPORATION, a Delaware corporation |
| | |
| | By: |
| | Name: Mar A. Prygocki, Sr. |
| | Name: Mark A. Prygocki, Sr. Title: Executive Vice President and CFO |
| State of Arizona) |) |
|) SS. | The state of the s |
| County of Maricopa) | ٧ |
| On this 3PD day of DECEMBE | , 2007 before me personally appeared the |
| | oing instrument and who acknowledged to me that he |
| executed the same of his own free will for the pu | irposes therein set forth. |
| | Marelyn Q. Luley Notary Public, |
| "OFFICIAL SEAL" Marilyn A. Luby | Notary Public, |
| (seal) Notary Public-Arizona Maricopa County Maricopa Foreign 8(2)2000 | Maricopa County, State of Arizona |
| (SCAT) My Commission Expires 8/2/2009 | My Commission Expires: $8/2/2009$ |
| | |
| | TARO PHARMACEUTICALS U.S.A., INC., |
| | a New York corporation |
| | <u>-</u> |
| | By: |
| | Name: Thomas McClary |
| | Title:Group Vice President and CFO |
| State of) | |
|) ss. | |
| County of) | |
| On this day of | , 2007 before me personally appeared the |
| foregoing individual, who executed the foregoing | ng instrument and who acknowledged to me that he/she |
| executed the same of his/her own free will for the | e purposes therein set forth. |
| | |
| | Notary Public, |
| | • |
| (seal) | County, State of |
| | My Commission Expires: |

IN TESTIMONY WHEREOF, the parties hereto have executed this Assignment by its proper officers thereunto duly authorized.

MEDICIS PHARMACEUTICAL

CORPORATION, a Delaware corporation

| | | Ву: |
|-------------|---|---|
| | | Name: Mark A. Prygocki, Sr. Title: Executive Vice President and CFO |
| State of Ar | · · · · · · · · · · · · · · · · · · · | |
| County of I | Maricopa) ss. | • |
| | day of individual, who executed the forene same of his own free will for the | , 2007 before me personally appeared the egoing instrument and who acknowledged to me that he purposes therein set forth. |
| | | Notary Public, |
| (seal) | | Maricopa County, State of Arizona My Commission Expires: |
| | | TARO PHARMACEUTICALS U.S.A., INC., a New York corporation By: Mosson & McClary |
| | | Name: Thomas McClary Title:Group Vice President and CFO |
| | New York Westchester }ss | |
| | individual, who executed the foreg he same of his/her own free will for | going instrument and who acknowledged to me that he/she the purposes therein set forth. |
| (seal) | ALEXANDER I. COSSIN Notary Public, State of New York Orange County Lic# 02CO4899276 Commission Expires June 8, 20// | Notary Public, ORANGE County, State of HEW YOR K My Commission Expires: Jove 11, 2011 |

EXHIBIT A

LICENSED MARKS

| | | | | | Applicable Canda |
|-------------------|----------------|--|------------|------------|--|
| Trademark | Country | Filing Date | Reg. No. | Issue Date | Applicable Goods |
| ALUSTRA | U.S. | 1/30/01 | 2,618,880 | 9/10/02 | Dermatological preparations. |
| ALUSTRA | Canada | 2/1/01 | TMA608,512 | 4/26/04 | Dermatological preparations for the treatment of pigmentation disorders. |
| LUSTRA | U.S. | 3/19/97 | 2,204,466 | 11/17/98 | Dermatological preparation. |
| LUSTRA | Canada | 7/11/97 | TMA547,412 | 6/28/01 | Dermatological preparations, namely, skin lighteners. |
| LUSTRA | Puerto Rico | 7/31/97 | 43,262 | 6/7/00 | Dermatological preparation. |
| LUSTRA and Design | U.S. | 4/16/99 | 2,329,449 | 3/14/00 | Dermatological preparation for use in the treatment of hyperpigmentation, melasma, and uneven pigmentation. |
| LUSTRA-AF | U.S. | 3/2/99 | 2,427,453 | 2/6/01 | Dermatological preparation. |
| LUSTRA-AF | Canada | 2/17/00 | TMA560,284 | 4/17/02 | Dermatological preparations, namely medicated topical preparations for treatment of pigmentation disorders. |
| LUSTRA ULTRA | U.S. | 8/5/04 | 3,133,987 | 8/22/06 | Dermatological preparations. |
| LUSTRA ULTRA | Canada | 8/4/04 Application No. 1,226,599 | N/A | N/A | Dermatological preparations for use in the treatment of post inflammatory hyper-pigmentation, and dyschromia. |
| LUSTRA-AF | Puerto Rico | 2/18/00 | 48,694 | 2/18/00 | Dermatological preparation. |
| SUNANDSKIN.COM | U.S. | 12/14/99 | 2,478,612 | 8/14/01 | Providing information in the field of skin care via the global computer network. |

3

RECORDED: 12/13/2007

TRADEMARK REEL: 003677 FRAME: 0823